TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction

Amsterdam UMC, location VUmc0 个研究点目标入组 25 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•1. Diagnosis of Heart failure with preserved ejection fraction (HFpEF):
•a) signs/and or symptoms of heart failure, NYHA II or higher (and ambulant).
•b) LVEF >50%
•c) evidence of LV diastolic dysfunction; with the exclusion of other significant co-morbidity (especially other severe cardiac conditions, severe kidney failure, parkinsonism) and able to comply the complete protocol (RHC, MRI/MRS).
•d. no other significant cardiac (e.g. significant valvular disease) or extra-cardiac condtion (e.g. severe COPD) that explains symptoms.
•2. Clinically stable (no change in diuretics >1 month), co-morbidities managed.
•3. Informed consent.

•1.Current acute decompensated heart failure, requiring augmented therapy with intravenous diuretics, vasodilator and/or inotropic drugs;
•2.Acute coronary syndrome, TIA/CVA, major surgery within the 3 months prior;
•3.Suspected septal scar (e.g. due to myocardial infarction) which prohibits the measurement of PCr/ATP with magnetic resonance spectroscopy (MRS))
•4.Unable to undergo the complete study protocol (right heart catheterization, MRI/MRS, 6-MWD)
•5.Contra-indication for trimetazidine (severe kidney failure with an eGFR <30ml/min, parkinsonism or patients requiring medication that cause parkinsonism)
•6.Doubt about compliance
•7.Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control
•8.Chronic absorption problems
•9.Estimated life-expectancy < 1 year.

发起方

Amsterdam UMC, location VUmc